Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients
Extrinsic AD and chronic lichenoid eczema are risk factors for poor response to 4-week dupilumab treatment, which suggests that AD patients with extrinsic and chronic lichenoid eczema may need more patience for long-term treatment or make other options.
Authors
- Linfeng Li (ORCID: https://orcid.org/0000-0002-8736-6464)
- Ling Yu (ORCID: https://orcid.org/0000-0002-6236-2117)
- Jianguo Li (ORCID: https://orcid.org/0000-0001-9431-2950)
- Shoumin Zhang (ORCID: https://orcid.org/0000-0002-7613-1088)
- Cheng Lian (ORCID: https://orcid.org/0000-0001-6929-1545)
Institutions
- Capital Medical University (CN)
- Zhengzhou University (CN)
- Henan Provincial People's Hospital (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/jaa.s508697
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00